Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

Pre- and Postoperative Neratinib for HER2-Positive Breast Cancer Brain Metastases: Translational Breast Cancer Research Consortium 022.

Freedman RA, Gelman RS, Agar NYR, Santagata S, Randall EC, Gimenez-Cassina Lopez B, Connolly RM, Dunn IF, Van Poznak CH, Anders CK, Melisko ME, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Moy B, Blackwell KL, Puhalla SL, Ibrahim N, Moynihan TJ, Nangia J, Tung N, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium (TBCRC).

Clin Breast Cancer. 2019 Aug 22. pii: S1526-8209(19)30657-3. doi: 10.1016/j.clbc.2019.07.011. [Epub ahead of print]

PMID:
31558424
2.

Standardized activities for lay patient navigators in breast cancer care: Recommendations from a citywide implementation study.

Freund KM, Haas JS, Lemon SC, Burns White K, Casanova N, Dominici LS, Erban JK, Freedman RA, James TA, Ko NY, LeClair AM, Moy B, Parsons SK, Battaglia TA.

Cancer. 2019 Aug 26. doi: 10.1002/cncr.32432. [Epub ahead of print]

PMID:
31449680
3.

FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer.

Drago JZ, Formisano L, Juric D, Niemierko A, Servetto A, Wander SA, Spring LM, Vidula N, Younger J, Peppercorn J, Yuen M, Malvarosa G, Sgroi D, Isakoff SJ, Moy B, Ellisen LW, Iafrate AJ, Arteaga CL, Bardia A.

Clin Cancer Res. 2019 Aug 1. doi: 10.1158/1078-0432.CCR-19-0138. [Epub ahead of print]

PMID:
31371343
4.

Impact of Timing on Measurement of Decision Quality and Shared Decision Making: Longitudinal Cohort Study of Breast Cancer Patients.

Sepucha KR, Langford AT, Belkora JK, Chang Y, Moy B, Partridge AH, Lee CN.

Med Decis Making. 2019 Jul 29:272989X19862545. doi: 10.1177/0272989X19862545. [Epub ahead of print]

PMID:
31354095
5.

Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer.

Medford AJ, Dubash TD, Juric D, Spring L, Niemierko A, Vidula N, Peppercorn J, Isakoff S, Reeves BA, LiCausi JA, Wesley B, Malvarosa G, Yuen M, Wittner BS, Lawrence MS, Iafrate AJ, Ellisen L, Moy B, Toner M, Maheswaran S, Haber DA, Bardia A.

NPJ Precis Oncol. 2019 Jul 16;3:18. doi: 10.1038/s41698-019-0090-5. eCollection 2019.

6.

Evaluation of the impact of a social media-focused intervention on reducing mental health stigma among pharmacy students.

Douglass M, Moy B.

Ment Health Clin. 2019 May 10;9(3):110-115. doi: 10.9740/mhc.2019.05.110. eCollection 2019 May.

7.

Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial).

Bellon JR, Guo H, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis M, Wolff AC, Carey LA, Overmoyer BA, Partridge AH, Hudis CA, Krop I, Burstein HJ, Winer EP, Tolaney SM.

Breast Cancer Res Treat. 2019 Jul;176(2):303-310. doi: 10.1007/s10549-019-05238-4. Epub 2019 Apr 19.

PMID:
31004299
8.

Addressing the Financial Burden of Cancer Clinical Trial Participation: Longitudinal Effects of an Equity Intervention.

Nipp RD, Lee H, Gorton E, Lichtenstein M, Kuchukhidze S, Park E, Chabner BA, Moy B.

Oncologist. 2019 Aug;24(8):1048-1055. doi: 10.1634/theoncologist.2019-0146. Epub 2019 Apr 15.

9.

Expanding Access to Cancer Clinical Trials for Patients With Mental Illness.

Irwin KE, Moy B, Fields LE, Callaway CA, Park ER, Wirth L.

J Clin Oncol. 2019 Jun 20;37(18):1524-1528. doi: 10.1200/JCO.18.01881. Epub 2019 Apr 15. No abstract available.

PMID:
30986118
10.

A Review on the Management of Biliary Complications after Orthotopic Liver Transplantation.

Moy BT, Birk JW.

J Clin Transl Hepatol. 2019 Mar 28;7(1):61-71. doi: 10.14218/JCTH.2018.00028. Epub 2018 Dec 3. Review.

11.

Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Tolaney SM, Guo H, Pernas S, Barry WT, Dillon DA, Ritterhouse L, Schneider BP, Shen F, Fuhrman K, Baltay M, Dang CT, Yardley DA, Moy B, Marcom PK, Albain KS, Rugo HS, Ellis MJ, Shapira I, Wolff AC, Carey LA, Overmoyer B, Partridge AH, Hudis CA, Krop IE, Burstein HJ, Winer EP.

J Clin Oncol. 2019 Aug 1;37(22):1868-1875. doi: 10.1200/JCO.19.00066. Epub 2019 Apr 2.

PMID:
30939096
12.

PIK3CA alterations and benefit with neratinib: analysis from the randomized, double-blind, placebo-controlled, phase III ExteNET trial.

Chia SKL, Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Kim SB, Jakobsen EH, Harvey V, Robert N, Smith J 2nd, Harker G, Zhang B, Eli LD, Ye Y, Lalani AS, Buyse M, Chan A.

Breast Cancer Res. 2019 Mar 11;21(1):39. doi: 10.1186/s13058-019-1115-2.

13.

TBCRC 022: A Phase II Trial of Neratinib and Capecitabine for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Anders CK, Melisko ME, Parsons HA, Cropp AM, Silvestri K, Cotter CM, Componeschi KP, Marte JM, Connolly RM, Moy B, Van Poznak CH, Blackwell KL, Puhalla SL, Jankowitz RC, Smith KL, Ibrahim N, Moynihan TJ, O'Sullivan CC, Nangia J, Niravath P, Tung N, Pohlmann PR, Burns R, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU; Translational Breast Cancer Research Consortium.

J Clin Oncol. 2019 May 1;37(13):1081-1089. doi: 10.1200/JCO.18.01511. Epub 2019 Mar 12.

PMID:
30860945
14.

The immune profile of small HER2-positive breast cancers: a secondary analysis from the APT trial.

Barroso-Sousa R, Barry WT, Guo H, Dillon D, Tan YB, Fuhrman K, Osmani W, Getz A, Baltay M, Dang C, Yardley D, Moy B, Marcom PK, Mittendorf EA, Krop IE, Winer EP, Tolaney SM.

Ann Oncol. 2019 Apr 1;30(4):575-581. doi: 10.1093/annonc/mdz047.

PMID:
30753274
15.

Effects of neratinib on health-related quality of life in women with HER2-positive early-stage breast cancer: longitudinal analyses from the randomized phase III ExteNET trial.

Delaloge S, Cella D, Ye Y, Buyse M, Chan A, Barrios CH, Holmes FA, Mansi J, Iwata H, Ejlertsen B, Moy B, Chia SKL, Gnant M, Smichkoska S, Ciceniene A, Martinez N, Filipović S, Ben-Baruch NE, Joy AA, Langkjer ST, Senecal F, de Boer RH, Moran S, Yao B, Bryce R, Auerbach A, Fallowfield L, Martin M.

Ann Oncol. 2019 Apr 1;30(4):567-574. doi: 10.1093/annonc/mdz016.

PMID:
30689703
16.

Longitudinal analysis of developmental changes in electroencephalography patterns and sleep-wake states of the neonatal mouse.

Rensing N, Moy B, Friedman JL, Galindo R, Wong M.

PLoS One. 2018 Nov 6;13(11):e0207031. doi: 10.1371/journal.pone.0207031. eCollection 2018.

17.

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Spring L, Niemierko A, Haddad S, Yuen M, Comander A, Reynolds K, Shin J, Bahn A, Brachtel E, Specht M, Smith BL, Taghian A, Jimenez R, Peppercorn J, Isakoff SJ, Moy B, Bardia A.

Breast Cancer Res Treat. 2018 Dec;172(3):733-740. doi: 10.1007/s10549-018-4959-8. Epub 2018 Sep 15.

PMID:
30220055
18.

Addressing Financial Barriers to Patient Participation in Clinical Trials: ASCO Policy Statement.

Winkfield KM, Phillips JK, Joffe S, Halpern MT, Wollins DS, Moy B.

J Clin Oncol. 2018 Sep 13:JCO1801132. doi: 10.1200/JCO.18.01132. [Epub ahead of print]

PMID:
30212297
19.

Endoscopic Features of Mucous Cap Polyps: A Way to Predict Serrated Polyps.

Moy BT, Forouhar F, Kuo CL, Devers TJ.

Clin Endosc. 2018 Jul;51(4):368-374. doi: 10.5946/ce.2017.155. Epub 2018 Apr 27.

20.

Patterns in Health Care Access and Affordability Among Cancer Survivors During Implementation of the Affordable Care Act.

Nipp RD, Shui AM, Perez GK, Kirchhoff AC, Peppercorn JM, Moy B, Kuhlthau K, Park ER.

JAMA Oncol. 2018 Jun 1;4(6):791-797. doi: 10.1001/jamaoncol.2018.0097.

21.

Intravascular Cooling Catheter-Related Venous Thromboembolism After Hypothermia: A Case Report and Review of the Literature.

Wang X, Moy BT, Hiendlmayr BJ, Krainski F, Duvall WL, Fernandez AB.

Ther Hypothermia Temp Manag. 2018 Jun;8(2):117-120. doi: 10.1089/ther.2017.0059. Epub 2018 Mar 23. Review.

PMID:
29570428
22.

AR Expression in Breast Cancer CTCs Associates with Bone Metastases.

Aceto N, Bardia A, Wittner BS, Donaldson MC, O'Keefe R, Engstrom A, Bersani F, Zheng Y, Comaills V, Niederhoffer K, Zhu H, Mackenzie O, Shioda T, Sgroi D, Kapur R, Ting DT, Moy B, Ramaswamy S, Toner M, Haber DA, Maheswaran S.

Mol Cancer Res. 2018 Apr;16(4):720-727. doi: 10.1158/1541-7786.MCR-17-0480. Epub 2018 Feb 16.

23.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
24.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update.

Van Poznak C, Somerfield MR, Barlow WE, Biermann JS, Bosserman LD, Clemons MJ, Dhesy-Thind SK, Dillmon MS, Eisen A, Frank ES, Jagsi R, Jimenez R, Theriault RL, Vandenberg TA, Yee GC, Moy B.

J Clin Oncol. 2017 Dec 10;35(35):3978-3986. doi: 10.1200/JCO.2017.75.4614. Epub 2017 Oct 16.

PMID:
29035643
25.

Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.

Van Poznak C, Somerfield MR, Moy B.

J Oncol Pract. 2017 Dec;13(12):822-824. doi: 10.1200/JOP.2017.027672. Epub 2017 Oct 16. No abstract available.

PMID:
29035617
26.

Rare Gastric Cardia Polyp Causing Complete Esophageal Obstruction.

Leroy K, Moy B, Rezaizadeh H.

ACG Case Rep J. 2017 Sep 27;4:e110. doi: 10.14309/crj.2017.110. eCollection 2017.

27.

Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.

Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes KS, Isakoff SJ, Ellisen LW, Smith BL, Specht M, Moy B, Bardia A.

J Natl Compr Canc Netw. 2017 Oct;15(10):1216-1223. doi: 10.6004/jnccn.2017.0158.

PMID:
28982747
28.

Survivorship Model of Care: Development and Implementation of a Nurse Practitioner-Led Intervention for Patients With Breast Cancer
.

Post KE, Moy B, Furlani C, Strand E, Flanagan J, Peppercorn JM.

Clin J Oncol Nurs. 2017 Aug 1;21(4):E99-E105. doi: 10.1188/17.CJON.E99-E105.

PMID:
28738044
29.

Clinical Management of Potential Toxicities and Drug Interactions Related to Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Practical Considerations and Recommendations.

Spring LM, Zangardi ML, Moy B, Bardia A.

Oncologist. 2017 Sep;22(9):1039-1048. doi: 10.1634/theoncologist.2017-0142. Epub 2017 Jul 13. Review.

30.

Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: A Cancer Care Ontario and American Society of Clinical Oncology Clinical Practice Guideline.

Dhesy-Thind S, Fletcher GG, Blanchette PS, Clemons MJ, Dillmon MS, Frank ES, Gandhi S, Gupta R, Mates M, Moy B, Vandenberg T, Van Poznak CH.

J Clin Oncol. 2017 Jun 20;35(18):2062-2081. doi: 10.1200/JCO.2016.70.7257. Epub 2017 Mar 6. Review.

PMID:
28618241
31.

A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer.

Baselga J, Morales SM, Awada A, Blum JL, Tan AR, Ewertz M, Cortes J, Moy B, Ruddy KJ, Haddad T, Ciruelos EM, Vuylsteke P, Ebbinghaus S, Im E, Eaton L, Pathiraja K, Gause C, Mauro D, Jones MB, Rugo HS.

Breast Cancer Res Treat. 2017 Jun;163(3):535-544. doi: 10.1007/s10549-017-4199-3. Epub 2017 Mar 21.

32.

Normalization of compression-induced hemodynamics in patients responding to neoadjuvant chemotherapy monitored by dynamic tomographic optical breast imaging (DTOBI).

Sajjadi AY, Isakoff SJ, Deng B, Singh B, Wanyo CM, Fang Q, Specht MC, Schapira L, Moy B, Bardia A, Boas DA, Carp SA.

Biomed Opt Express. 2017 Jan 4;8(2):555-569. doi: 10.1364/BOE.8.000555. eCollection 2017 Feb 1.

33.

Real world patterns of care in HER2-overexpressing breast cancer: Results of a survey of TEACH clinical trial investigators in 2011.

Chavarri-Guerra Y, St Louis J, Bukowski A, Soto-Perez-de-Celis E, Liedke PER, Symecko H, Moy B, Higgins M, Finkelstein DM, Goss PE.

Breast. 2017 Feb;31:197-201. doi: 10.1016/j.breast.2016.11.014. Epub 2016 Nov 25.

PMID:
27894048
34.

The Elimination of Cancer Health Disparities: Are We Ready to Do the Heavy Lifting?

Jackson JD, Moy B, Evans MK.

Oncologist. 2016 Dec;21(12):1411-1413. Epub 2016 Nov 7. No abstract available.

35.

No Conflict, No Interest.

Nipp RD, Moy B.

JAMA Oncol. 2016 Dec 1;2(12):1631-1632. doi: 10.1001/jamaoncol.2016.2726. No abstract available.

PMID:
27560041
36.

Distribution and Patterns of Industry-Related Payments to Oncologists in 2014.

Marshall DC, Moy B, Jackson ME, Mackey TK, Hattangadi-Gluth JA.

J Natl Cancer Inst. 2016 Jul 7;108(12). pii: djw163. doi: 10.1093/jnci/djw163. Print 2016 Dec.

37.

Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer: A Systematic Review and Meta-analysis.

Spring LM, Gupta A, Reynolds KL, Gadd MA, Ellisen LW, Isakoff SJ, Moy B, Bardia A.

JAMA Oncol. 2016 Nov 1;2(11):1477-1486. doi: 10.1001/jamaoncol.2016.1897. Review.

38.

Primary Follicular Lymphoma of the Gastrointestinal Tract: Case Report and Review.

Moy BT, Wilmot J, Ballesteros E, Forouhar F, Vaziri H.

J Gastrointest Cancer. 2016 Sep;47(3):255-63. doi: 10.1007/s12029-016-9847-z. Review.

PMID:
27277664
39.

Issues in Breast Cancer Survivorship: Optimal Care, Bone Health, and Lifestyle Modifications.

Melisko ME, Gradishar WJ, Moy B.

Am Soc Clin Oncol Educ Book. 2016;35:e22-9. doi: 10.14694/EDBK_159203. Review.

40.

Gastric Diverticulum: An Unusual Endoscopic Finding.

Moy BT, Marchioni Beery RM, Birk JW.

ACG Case Rep J. 2016 Apr 15;3(3):150-1. doi: 10.14309/crj.2016.31. eCollection 2016 Apr. No abstract available.

41.

Financial Burden of Cancer Clinical Trial Participation and the Impact of a Cancer Care Equity Program.

Nipp RD, Lee H, Powell E, Birrer NE, Poles E, Finkelstein D, Winkfield K, Percac-Lima S, Chabner B, Moy B.

Oncologist. 2016 Apr;21(4):467-74. doi: 10.1634/theoncologist.2015-0481. Epub 2016 Mar 14.

42.

Probable doxycycline-induced acute pancreatitis.

Moy BT, Kapila N.

Am J Health Syst Pharm. 2016 Mar 1;73(5):286-91. doi: 10.2146/ajhp150298.

PMID:
26896500
43.

Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, Robert NJ, Silovski T, Gokmen E, von Minckwitz G, Ejlertsen B, Chia SK, Mansi J, Barrios CH, Gnant M, Buyse M, Gore I, Smith J 2nd, Harker G, Masuda N, Petrakova K, Zotano AG, Iannotti N, Rodriguez G, Tassone P, Wong A, Bryce R, Ye Y, Yao B, Martin M; ExteNET Study Group.

Lancet Oncol. 2016 Mar;17(3):367-77. doi: 10.1016/S1470-2045(15)00551-3. Epub 2016 Feb 10.

PMID:
26874901
44.

Trends in the use of mastectomy in women with small node-negative breast cancer treated at US academic centers.

Vaz-Luis I, Hughes ME, Cronin A, Rugo HS, Edge SB, Moy B, Theriault RL, Hassett MJ, Winer EP, Lin NU.

Breast Cancer Res Treat. 2016 Feb;155(3):569-78. doi: 10.1007/s10549-016-3707-1. Epub 2016 Feb 11.

PMID:
26868124
45.

Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases.

Freedman RA, Gelman RS, Wefel JS, Melisko ME, Hess KR, Connolly RM, Van Poznak CH, Niravath PA, Puhalla SL, Ibrahim N, Blackwell KL, Moy B, Herold C, Liu MC, Lowe A, Agar NY, Ryabin N, Farooq S, Lawler E, Rimawi MF, Krop IE, Wolff AC, Winer EP, Lin NU.

J Clin Oncol. 2016 Mar 20;34(9):945-52. doi: 10.1200/JCO.2015.63.0343. Epub 2016 Feb 1.

46.

Identification of early breast cancer patient cohorts who may benefit from lapatinib therapy.

Strasser-Weippl K, Horick N, Smith IE, O'Shaughnessy J, Ejlertsen B, Boyle F, Buzdar AU, Fumoleau P, Gradishar W, Martin M, Moy B, Piccart-Gebhart M, Pritchard KI, Lindquist D, Rappold E, Finkelstein DM, Goss PE.

Eur J Cancer. 2016 Mar;56:85-92. doi: 10.1016/j.ejca.2015.12.024. Epub 2016 Jan 30.

PMID:
26829011
47.

Announcing a New Journal Section: Community Outreach.

Evans M, Moy B.

Oncologist. 2016 Jan;21(1):1. doi: 10.1634/theoncologist.2015-0494. Epub 2015 Dec 28. No abstract available.

48.

Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.

Dang C, Guo H, Najita J, Yardley D, Marcom K, Albain K, Rugo H, Miller K, Ellis M, Shapira I, Wolff AC, Carey LA, Moy B, Groarke J, Moslehi J, Krop I, Burstein HJ, Hudis C, Winer EP, Tolaney SM.

JAMA Oncol. 2016 Jan;2(1):29-36. doi: 10.1001/jamaoncol.2015.3709.

49.

Biological Subtype Predicts Risk of Locoregional Recurrence After Mastectomy and Impact of Postmastectomy Radiation in a Large National Database.

Tseng YD, Uno H, Hughes ME, Niland JC, Wong YN, Theriault R, Blitzblau RC, Moy B, Breslin T, Edge SB, Hassett MJ, Punglia RS.

Int J Radiat Oncol Biol Phys. 2015 Nov 1;93(3):622-30. doi: 10.1016/j.ijrobp.2015.07.006. Epub 2015 Jul 11.

PMID:
26461004
50.

Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus White Women and the Association of Racial Differences With Tumor Recurrence.

Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, Isakoff S, Ellisen LW, Bardia A.

J Clin Oncol. 2015 Nov 1;33(31):3621-7. doi: 10.1200/JCO.2015.62.2126. Epub 2015 Sep 14.

Supplemental Content

Support Center